Team:ZJU-China/project.htm

Backround

Camille J. Delebecque and his colleagues have designed and assembled RNA structures and used them as scaffolds for the spatial organization of bacterial metabolism (Fig.1). Scaffold D0 consists of PP7 and MS2 aptamer domains that bind PP7 and MS2 fusion proteins. As told above, our project is based on the existing scaffold D0. In order to make sure that we can do further work on it, we planned to repeat the work about scaffold D0.

Design

 

Fig.1 How RNA scaffold works. FA and FB represent two halves of EGFP. FA and MS2 are connected with a linker of 30bp. FB and PP7 did the same. The purple scaffold is scaffold D0. MS2 and PP7 can specifically bind to two stem-loops on scaffold, thus FA and FB get closer and fluoresce under excitation of 480nm.

 

Materials and Methods

1. Plasmids and Strains

pCJDFA and pCJDFB respectively comprising the gene of half split EGFP (fragment A and fragment B) and MS2 or PP7 protein were constructed by overlap extension PCR. (See the Overlap PCR protocal) Genes MS2, PP7 and pCJDD0 are provided by Dr. Camille J. Delebecque. pEGFP is provided by Prof. Jianzhong Shao.

Information of pCJDFA, pCJDFB and pCJDD0 are as follows:

1). pCJDFA: FA-MS2 cloned into T7 duet expression vectors pACYCDuet-1 Spr

2) pCJDFB (FB-PP7 cloned into T7 duet expression vector pCOLADuet-1) Kanr

3) pCJDD0 (Scaffold D0 cloned into T7 duet expression vector PETDuet) Ampr

4) BL21-star(DE3)

BL21-star(DE3) cells were used to co-express plasmids. The most important feature of BL21-star(DE3) is that it carries a mutated rne gene (rne131) which encodes a truncated RNase E enzyme that lacks the ability to degrade mRNA, resulting in an increase in mRNA stability.

2. Transformation and induction

Three groups of transformation were conducted. The first is BL21-star(DE3) transformed only with pCJDD0, the second with pCJDFA+pCJDFB, and the third with pCJDFA+pCJDFB+pCJDD0.

Pick the single colony to cultivate in 3mL liquid LB with relative resistances. And when OD reached 0.4, induce with 0.2mM IPTG for 2h at 25 degree.

Wash the bacteria twice with equivalent PBS. Then test the Fluorescence intensity (FI) and OD with Biotek Synergy Hybrid Reader.

Data was shown in Fig.3. The fluorescence of different expression systems are pictured by Olympus fluoview fv1000 confocal laser scanning microscope ( Fig.2)

They were transformed with the pCJDD0 (plasmid with scaffold D0) into BL21-star-(DE3).

Results

See relative results in RESULTS S0: Basic Scaffold.

Several mutations of RNA scaffold D0 have been designed and made. They show quite different characterizes and functions. With the experiment, more RNA scaffold mutations are characterized. Concept Library of RNA Scaffold is suggested.

What is the Library of RNA Scaffold for? Evolution! The variable of RNA structures accommodates a wide application prospect. Though the point mutation reduced uncertainty of selection and the blindness, trying to find a suitable construction is vast project. Various experimental methods, selection and modeling should be used in this part. By analyzing existing mutations, derivation can be made to construct and find an enhanced RNA scaffold. We called this process evolution.

The Library may contain changes of self, self-assemble, RNA-RNA interaction, RNA-protein interaction. Some examples are shown below.

Categories of mutants

1. Mutating arm length

changing the arm length of RNA scaffold D0. As the mechanism of D0 is reducing the distance of two key enzyme of the pathway, in other words, the output and reaction efficiency is depend on the local concentration. The two aptamer binding site in our project is on two hairpin arms witch are designed in the same length. The change of the arm length provides feasibility of distance-efficiency research. We used split GFP experiments. We made some mutations with different arm length, the result of D0M4 and D0M 5 split GFP experiment shows the light decreasing lend by split GFP FA-FB distance. The difference (PD0M4=0.079, PD0M5=0.025) suggests that the mutating arm length scaffold doesn’t provide an on/off switch but a definability one. It characterized the D0 in another way.

fig 1a. D0 is the original scaffold. D0 a-d were mutated to the scaffold with different aptamer arm length.

fig 1b. The result of arm length mutating. Both D0M4 and D0M5 scaffold half-on GEP.

2. Mutating aptamer binding site

Mutating the PP7 and MS2 binding sites prevented protein scaffolding. Preventing protein scaffolding lead to the key enzyme dissociation and the decrease of enzyme local concentration. By chancing the sequence of MS2 aptamer binding site, the fluorescent light decreased. D0M3 in our project is the molecular with mutated aptamer binding site. Split GFP experiment shows that there is a significant difference between D0 an D0M3(P≦0.05, fig2.c). Camille J. Delebecque has done the same work for the H2 biosynthesis pathway.

Fig2a. MS2 and PP7 bind to the scaffold and make GFP work.

Fig2b. By mutating aptamer binding site, scaffolding is stop.

Fig2c. significant difference between D0 an D0M3

3. Assemblage

adding extra sequence for self-, RNA-, protein-assemblage. The added sequence may be a riboswitch, RNA or protein binding site, self-assemble structure. Regulation molecular search is also wanted synchronously.

Applications and outlook

1. sRNA regulation

Simple an direct RNA-RNA interaction change the object RNA scaffold structure. As a Foundation regulation, it substantially enhances the possibilities of forthcoming experiment.

Fig3. The designed scaffold has a interaction to regulatory sRNA. Same mechanism, regulatory molecule can be changed to mRNA a. Turn off the scaffold by the competitive binding with aptamer binding site (green) b. The RNA scaffold has a secondary structural switch controls accessibility of sRNA-binding sites(blue) witch can change the arm length. Output regulated by arm length change. c. both methods were used. d. bind and release the object molecular.)

2. Protein expression (mRNA) regulation

RNA scaffold as a free molecular in cell can specific bind mRNA and protein. Binding molecular changes the structure of scaffold to release or combine something. So that oncogene and virogene can be found and controlled by the drug from RNA scaffold. The problem of cancer therapeutic drug side effecting may solved by it.

3. Self quenching（Self regulation）

Adding self binding site, a balance of “on” and “off” scaffolds is built. The relationship between the binding site size, CG bases, binding form and the rate binding molecular is urgently modeled. Forming dimerization and trimerization, the concentration of working scaffold could be regulated.

4. Polo-scaffold

Scaffold with intermolecular binding component. These scaffolds bind each other or bind through mediate molecular. And this binding mode has been proved both in vitro and vivo. The aggregation of molecular also makes artificial organelle achievable.

Fig4a. Dimerization and trimerization. Protein binding site is sealed off by the scaffolds themselves. Too much scaffold molecular lend to the self regulation.

Fig4b. Dimerization and trimerization. Protein binding site is sealed off by the scaffolds themselves. Too much scaffold molecular lend to the self regulation.

Fig4c. Polo-scaffold be made by head-tail binding.

Several RNA scaffold mutations are constructed and characterize, but they are the tip of the iceberg. There is still plenty to do in this part. The charms of library are the selection and combination. It introduces a new concept of biobrick combination mode.

Summary

This is a summary of the parts that we have submitted to the Registry of Standard Biological Parts. These parts include:

ncRNA scaffold generator: BBa_K738000, BBa_K738002

protein coding domains: BBa_K738004 , BBa_K738005 , BBa_K738006 , BBa_K738007

These parts have all been well characterized. Please visit the Registry of Standard Biological Parts for more information.

List

?	?	Name	Type	Description	Designer	Length
	W	BBa_K738000	Generator	RNA Scaffold generator	Huachun Liu	171
	W	BBa_K738002	Generator	Theophyline riboswitch regulated RNA Scoffold(clover version 2)	Huachun Liu	209
	W	BBa_K738004	Generator	FA-2X-MS2;Split GFP N-terminal domain fused with MS2 protein	Huachun Liu	1284
	W	BBa_K738005	Coding	FB-2X-PP7;Split GFP C-terminal domain fused with PP7 protein	Huachun Liu	654
		BBa_K738006	Coding	FA: Split GFP N-terminal domain	Huachun Liu	480
		BBa_K738007	Coding	FB, Split GFP C-terminal domain	Huachun Liu	255

Future work

Theophylline responded RNA riboscaffold

We have designed two RNA riboscaffold responded to theophylline. Unfortunately, we only managed to submit one of them (BBa_K738002) to the Registry of Biological Parts in time (that means before September 26).

We have started the work of constructing a second theophylline responded RNA riboscaffold clover vision 3(but not finished). Clover vision 3 is different with BBa_K738002 in 3D structure, which may lead to results that are far away from that of BBa_K738002.

Please visit here for more information.

Library

We plan to develop a RNA scaffold library that offers more tunable responses. We’ve got several members in this library by now and our ultimate goal is acquiring a series of members which span a large acceleration rate range from about 10% to 90%. Thus, researchers may be able to choose a member in the library to acquire the targeted acceleration rate easily.

Pathway of producing IAA

Accelerating production of IAA with RNA scaffold has been proved to be efficient. Two enzymes, IaaH (BBa_K515000) and IaaM (BBa_K515001), are related to the process. We’ve fused IaaH and IaaM with MS2 and PP7 respectively to get IaaM-2X-MS2 and IaaH-2X-PP7, which are able to bind on RNA scaffold. We plan to make and submit this two protein as parts later. Thus, we’d like to regulate the biosynthesis process efficiency with RNA riboscaffold. We plan to submit BBa_K738014 and BBa_738015 later.

S0: BASIC RNA SCAFFOLD

Contrasted to the fluorescence intensity (FI) of the E.coli which only express FA-MS2 and FB-PP7 fusion proteins, the fluorescence intensity of the E.coli with scaffold D0 was obviously increased. Thus, it was possible for us to carry out our development and reformation of RNA scaffold.

Fig.1 FI of Split GFPs without or with RNA scaffold. A. BL21*(DE3) transformed with pCJDFA and pCJDFB. B. BL21*(DE3) transformed with pCJDFA, pCJDFB and pCJDD0. The contrast of FI obviously shown that RNA scaffold D0 could bind split GFPs together, so that split GFPs could fluoresce. (Pictures were obtained with Olympus fluoview fv1000 confocal laser scanning microscope, using a 60X objective.)

Fig.2 FI/OD of different transformation groups. There exist significant differences among three groups. And as expected, split GFPs with scaffold D0 together can fluoresce stronger than those without scaffold.

Reference:

1. Thodey, K. & Smolke, C.D. Bringing It Together with RNA. Science 333, 412-413 (2011).
2. Delebecque, C.J., Lindner, A.B., Silver, P.A. & Aldaye, F.A. Organization of Intracellular Reactions with Rationally Designed RNA Assemblies. Science 333, 470-474 (2011).

S1: RIBOSCAFFOLD

1. Scaffold

Fig.3 Different RNA scaffold’s effect on split GFP showing by fluorescence microscopy. The BL21*DE3 of the E. coli were transformed with pCJDFA+pCJDFB, pCJDFA+pCJDFB + pCJDD0, and pCJDFA+pCJDFB + pZCCOV 2 (0.5 mM theophylline adding). As expected, strains without RNA scaffold did not fluoresce. Upon the existence of RNA scaffold, many of the cells emitted fluorescence indicating a substantial amount of split GFP combination is permitted because of the function of RNA scaffold. The brightfield images in the right column depict all bacterial cells. The GFP images in the left column depict bacterial cells which emitted fluorescence.

Fig.4 Biotek Synergy H1 Hybrid Reader controlled experiments. The BL21*DE3 of the E. coli were transformed with figure showing plasmids. (0.5 mM theophylline was adding in strains containing clover 2).

`luminescence \quad efficiency \quad of \quad clover 2=\frac{\frac{FI}{OD(FA+FB+clover 2)}-\frac{FI}{OD(FA+FB)}}{\frac{FI}{OD(FA+FB)}}=\frac{53425-23779}{23779}=125\%`

`luminescence \quad efficiency \quad of \quad D0=\frac{\frac{FI}{OD(FA+FB+clover 2)}-\frac{FI}{OD(FA+FB)}}{\frac{FI}{OD(FA+FB)}}=\frac{38288-23779}{23779}=61\%`

The original intention of our designing RNA scaffold clover 2 is to create a regulatory scaffold which can tune its conformation thus have various functions. To our surprise, clover version 2, when adding optimal Theophylline concentration 0.5mM, happens to be a more powerful scaffold which helps two halves of GFP’s combination and give out light strongly.

One possible reason is in clover version 2, distance between MS2 aptamer and PP7 aptamer is closer than in D0 (showing in 04 S1 Rboscaffold Fig.4 and Fig.6), so that when binding phage coat proteins, FA and FB on clover version 2 were set closer than on D0. We submit the inference that when RNA scaffold binds enzymes, clover version 2 draws two enzymes nearer than D0 thus has more ability to accelerate the enzymatic reaction.

2. Regulate and control by Theophylline

When the concentration of Theophylline is in the range from 0mM to 0.5mM, the concentration of Theophylline and the resulting fluorescence intensity are directly proportional.

Theophylline concentration beyond certain extent will be hazardous to cells and how it affects cells depends on strain type. The study by NYMU Taipei 2010 alerted adding more than 4mM of Theophylline would cause E. coli to die. In our experiments, we find that after adding more than 0.5mM, the Theophylline spectrum curve would be invalid. As a result, we pick up data with concentrations below 0.5mM to analyze as the E. coli cell would be unstable or the regulation of the Theophylline aptamer would not be accurate.

Fig.5 origin data of clover 2 regulatory tests. First line of each form is different treatments of Theophylline concentration and data in table cells are fluorescence intensity/ OD.

Fig.6 7 tests of fluorescence/ OD change over theophylline concentration. There’s evident positive correlation in between.

Then we build several SAS models to analyze data with SAS software GLM procedure between 0-0.5mM Theophylline concentrations of treatments, choosing” clover version 2: different treatments versus blocks” test 5-7 to run a SAS model.

ANOVA result P-value shows that Theophylline concentrations have significant impact on fluorescence intensity of clover version 2 and almost no impact on D0. That is to say, our designed RNA scaffold clover version 2 can be regulated and controlled by Theophylline within 0-0.5mM not for random errors or common phenomenon in RNA scaffolds.

If you want more details about SAS source programs and software computational results, please click here [code].

1. Angel Riboscaffold

This is an extension application of our designed clover series of riboscaffold in drug diliver therapy. Some diseases, such as Cancer, will release some small molecular or change microenvironments beside it thus produce detectable signals. Different from using a biosensor to detect these signals, we utilize our scaffold’s aptamer, accompanying with the production of medicine target the disease. If we change Theophylline aptamer into nidus(disease) molecular aptamer, when riboscaffold bind nidus molecular and change conformation, MS2 aptamer & PP7 aptamer are going to set closer. Enzymes which combining MS2 aptamer & PP7 aptamer and producing drugs are ready to catalyze thus bring out targeting agents. It turns out to be a one-stop agency, once detect the focus of diease, will generate corresponding drug targeting the diease.

Fig1. Riboscaffold which can detect and treat diseases.

2. Shining Riboscaffold

Fi2. Aptamers that can shine upon binding.

Paige[1] has reported some RNA aptamers that can bind fluorophores, which are small compounds, and in this way resemble the chemical bonds in GFP, then give out fluorescence.

If we use these aptamers in replace of the theophylline aptamer on our riboscaffold, we can make the riboscaffold shining upon the binding of signal compounds mentioned above. This is a cool method to visualize the states, dynamics and localization of riboscaffold in the living cell.

3. LEGO Riboscaffold

Riboscaffold has unbelievable ability to extend itself through base pairing with each other, just like LEGO bricks! The assembly of LEGO riboscaffolds can load more enzymes and to a large degree accelerate the reaction or artificially construct a longer pathway with high efficiency. For example, artificial TCA cycle abd artificial EMP are promising results. The following pictures show our wide imagination of the possible structure of LEGO riboscaffolds.

But how to obtain these LEGO riboscaffolds? Wachtveitlb[2] has reported a fantastic method to detect RNA-RNA interaction by introducing fluorophores like 1-ethynylpyrene into the 2-position of RNA adenosine. When two single-stranded RNAs with this fluorophore base pair with each other, the fluorescence spectrum changes and thus suggesting their interaction. So it is hopeful to find the desired riboscaffolds as LEGO bricks by selecting from the library!

Fig3.1.(Upper Left) LEGO bricks.
Fig3.2.(Upper right) Long scaffold that has multiple binding sites.
Fig3.3.(Lower Left) A possible device built by LEGO riboscaffold.
Fig3.4.(Lower Right) Sheets and tubes constructed by LEGO riboscaffolds in vivo. [6]

4. Activator scaffold

In eukaryote, there are naturally produced long non-coding RNAs that attract more and more attention these days and display intriguing potential to act as scaffolds [3]. And our riboscaffold can mimic them and bring their functions to prokaryote. One of the functions is combining related transcription factors and bring them to promoter, as a result enhance the expression of target gene. That is because ncRNA can binds both DNA and Proteins, and can travel freely between nucleus and cytoplasm, which displays great advantage as a bridge.

Aptamers can be selected in vitro against nearly any target of choice. There are RNA aptamers that can specifically bind some transcriptional regulator. For example, Hunsicker [4] has selected one RNA aptamer that can bind TetR, which usually binds on operator sequence and repress gene expression. So once aptamers mentioned above are designed into a riboscaffold, it can initiate the expression of target genes with higher efficiency.

Fig3. Riboscaffold that can bring transcription factors to promoters.

5. Medicine & Health

To date, many groups have successfully identified aptamers with a variety of functions, including inhibitory and decoy-like aptamers, regulatable aptamers, multivalent/agonistic aptamers, and aptamers that act as delivery vehicles [5].

By designing these different aptamers into our RNA scaffold, we can endow our scaffold various potential applications in therapeutics and/or diagnostics.

For instance, designing inhibitory aptamers that targets VEGF into our RNA scaffold can be used to treat the wet age-related macular degeneration and that has been approved by the FDA in December 2004.

Designing Decoy-like aptamers that can mimic the target sequce of the proteins into our RNA scaffold can be used as decoys to inhibit binding of transcriptional factors such as HIV-tat, NF-κB, and E2F to their cognate sequences on DNA and thus prevent transcription of target genes and may result in powerful therapeutics for treating many human pathologies.

Designing aptamers behavior as delivery tools into our RNA scaffold can be used to deliver not only some siRNAs to target cells but also toxins, radioisotopes, and chemotherapeutic agents encapsulated in nanoparticles.

References:

[1] Jeremy S. Paige, Karen Y. Wu, Samie R. Jaffrey, RNA Mimics of Green Fluorescent Protein science, 2011 vol 333, 642-646.
[2] Josef Wachtveitlb, Joachim W. Engels, ect. RNA as scaffold for pyrene excited complexes, Bioorganic & Medicinal Chemistry 16 (2008) 19-26.
[3] Mitchell Guttman, John L. Rinn. Modular regulatory principles of large non-coding RNAs. Nature. 2012 Feb 15;482(7385):339-46.
[4] Anke Hunsicker, Markus Steber, ect. An RNA Aptamer that Induces Transcription, Chemistry & Biology, 2009,Volume 16, Issue 2, 173–180.
[5] Kristina W. Thiel and Paloma H. Giangrande, Therapeutic Applications of DNA and RNA Aptamers. Oligonucleotides, 2009, Volume 19, Number 3, 209-222.
[6] Thodey, K. & Smolke, C.D. Bringing It Together with RNA. Science 333, 412-413 (2011).